ZTS is in a longer-term uptrend that should continue when the weakness in the broader market subsides.
I like the risk/reward set up now.
The stock has broken a long-term downtrend, which gets my attention.
We now have two new price targets.
We have new price targets for soaring shares of PFE. Let's check the charts.
Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022
Here's how aggressive traders could play this biotech giant -- and our targets for the name.
This quartet has had a rough 2021 but could be in for a rebound next year once investors harvest their losses in the shares.
The bulls are back in charge.
Here's our next price target.